Details for Patent: 6,048,844
✉ Email this page to a colleague
Title: | Treatment of conditions and disease |
Abstract: | A combination for administration to a mammal which combination employes a therapeutically effective amount of medicinal and/or therepeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scarr tissue) at the site to be treated, through the cell membrane into the individual cells to be treated. |
Inventor(s): | Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel S. (Toronto, CA) |
Assignee: | Hyal Pharmaceutical Corporation (Mississauga, CA) |
Filing Date: | Jun 05, 1995 |
Application Number: | 08/461,565 |
Claims: | 1. A method of treating a condition or disease in a mammal involving tissue selected from the group consisting of underperfused tissue and pathological tissue comprising administering to the mammal a therapeutically effective dosage amount of an agent selected from the group consisting of a medicine and a therapeutic agent and combinations thereof to treat the disease or condition and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to facilitate the penetration of the agent through the tissue at a site to be treated through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10 mg and less than 1000 mg. 2. A dosage amount of a pharmaceutical composition for treating pain involving tissue selected from the group consisting of underperfused tissue and pathological tissue, said dosage amount comprising a therapeutically effective amount of a non-steroidal anti-inflammatory agent (NSAID) to treat the pain and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage amount greater than 10 mg. 3. The dosage amount of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate. 4. The dosage amount of claim 2 or 3 wherein the non-steroidal anti-inflammatory is selected from the group consisting of indomethacin, naproxen, tromethamine salt of Ketorolac and combinations thereof. 5. A method of treating back pain involving tissue selected from the group consisting of underperfused tissue and pathological tissue, the method comprising the administration of a therapeutically effective amount of a non-steroidal anti-inflammatory agent to treat the pain and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10 mg. 6. The method of claim 5 wherein the form of hyaluronic acid is sodium hyaluronate. 7. The method of claim 5 or 6 wherein the non-steroidal anti-inflammatory is selected from the group consisting of indomethacin, naproxen, tromethamine salt of Ketorolac and combinations thereof. 8. A method of treating a condition involving underperfused tissue and pathological tissue selected from the group consisting of bone pain, muscle pain and inflammation and combinations thereof, the method comprising administration of an effective amount of Ascorbic Acid (Vitamin C) and a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof to facilitate the agent at a site to be treated by the agents passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10 mg. 9. The method of claim 8 wherein the form of hyaluronic acid is sodium hyaluronate. 10. A method of treating a condition involving underperfused tissue and pathological tissue selected from the group consisting of bone pain, muscle pain and inflammation and combinations thereof, the method comprising the administration of a sufficient amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof and a non-steroidal anti-inflammatory agent wherein said form of hyaluronic acid facilitates the agent at a site to be treated by the agent passing through the tissue through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10 mg. 11. The method of claim 10 wherein the form of hyaluronic acid is sodium hyaluronate and the non-steroidal anti-inflammatory is selected from the group consisting of indomethacin, naproxen, tromethamine salt of ketoralac and combination thereof. 12. The dosage amount of claim 2 or 3 wherein the dosage amount of the form of hyaluronic acid is less than 3000 mg. 13. The method of claim 5 or 6 wherein the amount of the form of hyaluronic acid is no greater than 3000 mg. 14. The method of claim 3, 9, 10 or 12 wherein the amount of the form of hyaluronic acid is no greater than 3000 mg. |